Table of Contents
Introduction
Nilotinib is an oral anticancer drug used mainly in Philadelphia chromosome-positive chronic myeloid leukemia, commonly abbreviated as Ph+ CML. It belongs to the BCR-ABL tyrosine kinase inhibitor class. The most widely known brand name is Tasigna, and another formulation is Danziten. Nilotinib is pharmacologically related to imatinib but was designed to bind the BCR-ABL kinase more strongly and selectively.
Chronic myeloid leukemia is commonly driven by the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. This translocation forms the BCR-ABL fusion gene. The BCR-ABL gene produces an abnormal tyrosine kinase protein that continuously sends growth and survival signals to myeloid cells. This uncontrolled signaling causes excessive proliferation of leukemic cells.
Nilotinib acts by inhibiting the BCR-ABL tyrosine kinase. By blocking this abnormal kinase, nilotinib reduces leukemic cell proliferation, promotes apoptosis of abnormal cells, and helps achieve hematologic, cytogenetic, and molecular responses in patients with Ph+ CML. For exam purposes, nilotinib should be remembered as a second-generation BCR-ABL tyrosine kinase inhibitor used in Ph+ CML, with important safety warnings for QT prolongation and sudden death.
Tasigna is indicated for adult and pediatric patients at least 1 year of age with newly diagnosed Ph+ CML in chronic phase, adults with chronic or accelerated phase Ph+ CML resistant or intolerant to prior therapy including imatinib, and pediatric patients at least 1 year of age with chronic or accelerated phase Ph+ CML resistant or intolerant to prior TKI therapy. Danziten is labeled for adult patients with newly diagnosed Ph+ CML in chronic phase and adult patients with chronic or accelerated phase Ph+ CML resistant or intolerant to prior therapy including imatinib.
Mechanism of Action (Step-wise)
Step 1: Philadelphia chromosome forms the BCR-ABL fusion gene
In chronic myeloid leukemia, a reciprocal translocation occurs between chromosome 9 and chromosome 22. This is written as t(9;22). The shortened chromosome 22 is called the Philadelphia chromosome. This genetic abnormality creates the BCR-ABL fusion gene.
Step 2: BCR-ABL produces a continuously active tyrosine kinase
The BCR-ABL fusion gene codes for an abnormal tyrosine kinase protein. Unlike normal tyrosine kinases, this abnormal kinase remains constitutively active. This means it keeps sending growth signals even when the cell does not require them.
Step 3: Abnormal kinase signaling activates leukemic pathways
BCR-ABL activates several downstream signaling pathways involved in cell growth and survival. Important pathways include RAS/MAPK, PI3K/AKT, and JAK/STAT signaling. These pathways increase proliferation, reduce apoptosis, and allow abnormal myeloid cells to survive longer than normal cells.
Step 4: Leukemic myeloid cells multiply excessively
Because BCR-ABL signaling remains active, leukemic myeloid cells undergo uncontrolled proliferation. This leads to increased white blood cell counts, bone marrow expansion, splenomegaly, and other clinical features of chronic myeloid leukemia.
Step 5: Nilotinib binds to the ABL kinase domain
Nilotinib binds to the kinase domain of the ABL portion of the BCR-ABL protein. It stabilizes the inactive conformation of the ABL kinase domain, preventing the kinase from functioning normally. This is the central molecular action of nilotinib.
Step 6: ATP binding and phosphorylation are inhibited
Tyrosine kinases normally transfer phosphate groups from ATP to tyrosine residues on target proteins. Nilotinib inhibits this process by blocking the catalytic activity of BCR-ABL. As a result, autophosphorylation of BCR-ABL and phosphorylation of downstream signaling proteins are reduced.
Step 7: Downstream growth and survival signaling decreases
When BCR-ABL phosphorylation is inhibited, downstream signaling through RAS/MAPK, PI3K/AKT, and JAK/STAT pathways decreases. This reduces leukemic cell proliferation and survival signaling.
Step 8: Apoptosis of leukemic cells increases
By removing the abnormal survival advantage created by BCR-ABL, nilotinib allows leukemic cells to undergo apoptosis. Apoptosis is programmed cell death. This helps reduce the burden of Philadelphia chromosome-positive leukemic cells.
Step 9: Hematologic and molecular disease control improves
The therapeutic result is reduction in leukemic cell counts and improvement in bone marrow function. With effective treatment, patients may achieve complete hematologic response, cytogenetic response, and molecular response measured by BCR-ABL transcript levels.
Step 10: Nilotinib may inhibit some related kinases
Although nilotinib is primarily used for BCR-ABL inhibition, it can also inhibit other kinases such as PDGFR, c-KIT, CSF-1R, and DDR1 at certain concentrations. However, the key exam-relevant mechanism is inhibition of BCR-ABL tyrosine kinase in Ph+ CML.
Step 11: Nilotinib can overcome some imatinib-resistant mutations
Nilotinib has activity against many BCR-ABL mutations associated with imatinib resistance. However, it is not effective against all mutations. The T315I mutation is a classic mutation associated with resistance to several BCR-ABL inhibitors, including imatinib, nilotinib, and dasatinib.
Pharmacokinetics
Nilotinib is administered orally. Tasigna is available as capsules, while Danziten is available as tablets. These formulations are not directly interchangeable on a milligram-per-milligram basis because their dosage strengths and pharmacokinetic properties differ. This is a clinically important safety point to prevent underdosing or overdosing.
Tasigna capsules are taken twice daily approximately 12 hours apart on an empty stomach. Food should be avoided for at least 2 hours before and 1 hour after taking Tasigna because food can increase nilotinib exposure and may increase the risk of QT prolongation. Danziten tablets are taken twice daily and may be taken with or without food according to its product labeling.
Nilotinib is highly protein bound, with approximately 98% serum protein binding. Peak concentrations of Tasigna are reached about 3 hours after oral administration. Nilotinib is metabolized mainly in the liver by CYP3A4. Therefore, strong CYP3A4 inhibitors can increase nilotinib exposure and toxicity, while strong CYP3A4 inducers can reduce drug exposure and effectiveness.
Important interacting drugs include azole antifungals, macrolide antibiotics, HIV protease inhibitors, rifampin, carbamazepine, phenytoin, and St. John’s wort. Drugs that prolong the QT interval should generally be avoided because nilotinib itself can prolong QT.
Nilotinib is eliminated mainly through feces. Renal excretion is not the major route. Hepatic impairment can increase exposure, so dose adjustment or caution is needed in patients with baseline hepatic dysfunction.
Clinical Uses
Nilotinib is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Its most important use is in chronic phase Ph+ CML, especially in newly diagnosed patients or in patients who are resistant or intolerant to imatinib.
Nilotinib is also used in accelerated phase Ph+ CML in patients who are resistant or intolerant to prior therapy that included imatinib. Accelerated phase disease is more advanced than chronic phase and requires careful monitoring and specialist management.
Tasigna has pediatric indications for patients at least 1 year of age with newly diagnosed Ph+ CML in chronic phase and for pediatric patients with chronic or accelerated phase Ph+ CML resistant or intolerant to prior TKI therapy. Danziten labeling includes adult indications, while additional pediatric use information remains associated with Tasigna labeling.
Another important concept is treatment-free remission. Some adult patients with chronic phase Ph+ CML who have received nilotinib for at least 3 years and achieved a sustained deep molecular response may be considered for treatment discontinuation under strict monitoring. This is not casual stopping of therapy; it requires validated BCR-ABL transcript testing and close follow-up.
Nilotinib is not a general chemotherapy drug for all leukemias. Its use is mainly guided by the presence of the Philadelphia chromosome or BCR-ABL fusion in CML.
Adverse Effects
The most serious safety warning of nilotinib is QT prolongation and sudden death. Nilotinib can prolong cardiac ventricular repolarization, increasing the risk of torsades de pointes, syncope, seizure, or death. ECG monitoring is recommended at baseline, about 7 days after starting therapy, periodically thereafter, and after dose adjustments.
Nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Potassium and magnesium abnormalities should be corrected before starting treatment and monitored during therapy. Strong CYP3A4 inhibitors and other QT-prolonging drugs should generally be avoided.
Myelosuppression is another important adverse effect. Nilotinib can cause thrombocytopenia, neutropenia, and anemia. Complete blood counts should be monitored regularly, especially during the early months of therapy.
Cardiac and arterial vascular occlusive events can occur. These may include ischemic heart disease, peripheral arterial occlusive disease, and cerebrovascular events. Cardiovascular risk factors such as diabetes, hypertension, hyperlipidemia, and smoking history should be assessed and managed.
Nilotinib can cause pancreatitis and elevated serum lipase. Patients with abdominal pain and elevated lipase require evaluation. Hepatotoxicity can also occur, so liver function tests should be monitored.
Common adverse effects include rash, pruritus, nausea, vomiting, diarrhea, constipation, headache, fatigue, arthralgia, myalgia, cough, nasopharyngitis, pyrexia, night sweats, and abdominal discomfort. Laboratory abnormalities may include elevated bilirubin, elevated liver enzymes, electrolyte abnormalities, hyperglycemia, and lipid abnormalities.
Other important warnings include tumor lysis syndrome, hemorrhage, fluid retention, effects on growth and development in pediatric patients, and embryo-fetal toxicity. Women of reproductive potential should use effective contraception during treatment and for the recommended period after the last dose.
Comparative Analysis
Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor. It is commonly compared with imatinib, dasatinib, bosutinib, and ponatinib.
Imatinib is the first-generation BCR-ABL inhibitor and was the first major targeted therapy for CML. It inhibits BCR-ABL, KIT, and PDGFR. Nilotinib was designed to bind BCR-ABL more strongly than imatinib and may produce faster and deeper molecular responses in some patients, but it has important QT and vascular risk considerations.
Dasatinib is another second-generation BCR-ABL inhibitor. Unlike nilotinib, dasatinib also inhibits SRC family kinases. Dasatinib is associated with adverse effects such as pleural effusion and pulmonary arterial hypertension. Nilotinib is more strongly associated with QT prolongation, metabolic abnormalities, and arterial vascular occlusive events.
Bosutinib is also a BCR-ABL inhibitor with SRC inhibition. It commonly causes gastrointestinal adverse effects such as diarrhea and may cause hepatotoxicity. It has less emphasis on QT prolongation compared with nilotinib but still requires careful monitoring.
Ponatinib is a third-generation BCR-ABL inhibitor and is important because it has activity against the T315I mutation. However, ponatinib has a high risk of arterial occlusive events and is generally reserved for resistant disease or specific mutations.
Compared with traditional cytotoxic chemotherapy, nilotinib is more targeted because it acts on the abnormal BCR-ABL kinase driving Ph+ CML. However, targeted does not mean harmless. Its cardiac, vascular, hepatic, pancreatic, and hematologic toxicities are clinically significant.
MCQs
- Nilotinib belongs to which pharmacological class?
a) BCR-ABL tyrosine kinase inhibitor
b) Alkylating agent
c) Antimetabolite folate antagonist
d) Proteasome inhibitor
Answer: a) BCR-ABL tyrosine kinase inhibitor
- The most common brand name of nilotinib is:
a) Gleevec
b) Tasigna
c) Sprycel
d) Bosulif
Answer: b) Tasigna
- Nilotinib is mainly used in which disease?
a) Philadelphia chromosome-positive chronic myeloid leukemia
b) Acute bacterial meningitis
c) Rheumatoid arthritis
d) Hodgkin lymphoma only
Answer: a) Philadelphia chromosome-positive chronic myeloid leukemia
- The Philadelphia chromosome results from which translocation?
a) t(8;14)
b) t(9;22)
c) t(15;17)
d) t(11;14)
Answer: b) t(9;22)
- The BCR-ABL fusion protein has which abnormal activity?
a) Constitutive tyrosine kinase activity
b) Cyclooxygenase inhibition
c) Acetylcholinesterase activation
d) Histamine receptor blockade
Answer: a) Constitutive tyrosine kinase activity
- Nilotinib binds and stabilizes which conformation of the ABL kinase domain?
a) Inactive conformation
b) Fully activated conformation
c) Ribosomal conformation
d) DNA-bound conformation only
Answer: a) Inactive conformation
- Which downstream pathways are reduced after BCR-ABL inhibition by nilotinib?
a) RAS/MAPK, PI3K/AKT, and JAK/STAT
b) COX-1 and COX-2 only
c) GABA and glycine pathways
d) Histamine H1 and H2 pathways
Answer: a) RAS/MAPK, PI3K/AKT, and JAK/STAT
- The final cellular effect of nilotinib on leukemic cells is mainly:
a) Increased leukemic cell survival
b) Reduced proliferation and increased apoptosis
c) Increased bacterial killing
d) Increased platelet aggregation
Answer: b) Reduced proliferation and increased apoptosis
- Which mutation is classically associated with resistance to several BCR-ABL inhibitors including nilotinib?
a) T315I
b) EGFR L858R
c) KRAS G12C
d) JAK2 V617F
Answer: a) T315I
- The most important boxed warning associated with nilotinib is:
a) QT prolongation and sudden death
b) Irreversible hearing loss
c) Severe hypoglycemia
d) Pulmonary fibrosis in all patients
Answer: a) QT prolongation and sudden death
- Tasigna capsules should generally be taken:
a) With a high-fat meal
b) On an empty stomach
c) Only with grapefruit juice
d) Immediately after antacid every time
Answer: b) On an empty stomach
- Nilotinib is mainly metabolized by which enzyme?
a) CYP3A4
b) CYP2C19 only
c) Monoamine oxidase
d) Acetylcholinesterase
Answer: a) CYP3A4
- Which electrolyte abnormality is a contraindication or major safety concern with nilotinib?
a) Hypomagnesemia
b) Mild hypernatremia only
c) Hypercalcemia only
d) Low bicarbonate only
Answer: a) Hypomagnesemia
- Which adverse effect requires complete blood count monitoring during nilotinib therapy?
a) Myelosuppression
b) Cataract formation only
c) Gingival hyperplasia
d) Nephrolithiasis only
Answer: a) Myelosuppression
- Which BCR-ABL inhibitor is especially known for activity against the T315I mutation?
a) Ponatinib
b) Nilotinib
c) Imatinib
d) Dasatinib
Answer: a) Ponatinib
FAQs
What is the mechanism of action of nilotinib?
Nilotinib inhibits the BCR-ABL tyrosine kinase. It binds to the ABL kinase domain, stabilizes its inactive conformation, reduces abnormal phosphorylation signaling, decreases leukemic cell proliferation, and promotes apoptosis.
What is the brand name of nilotinib?
The best-known brand name of nilotinib is Tasigna. Danziten is another nilotinib formulation available as tablets. These products are not automatically interchangeable on a milligram-per-milligram basis.
What disease is nilotinib used for?
Nilotinib is used mainly for Philadelphia chromosome-positive chronic myeloid leukemia, including newly diagnosed chronic phase disease and chronic or accelerated phase disease resistant or intolerant to prior therapy such as imatinib.
Why is nilotinib called a targeted therapy?
Nilotinib is called targeted therapy because it acts on the abnormal BCR-ABL tyrosine kinase that drives Ph+ CML. It does not work like broad traditional chemotherapy, although it still has serious adverse effects.
What is the most important safety warning of nilotinib?
The most important warning is QT prolongation and sudden death. ECG monitoring, electrolyte correction, and avoidance of QT-prolonging drugs and strong CYP3A4 inhibitors are important.
Why should Tasigna be taken on an empty stomach?
Food can increase nilotinib exposure from Tasigna capsules, which may increase the risk of QT prolongation. Therefore, patients should avoid food for at least 2 hours before and 1 hour after taking Tasigna.
How is nilotinib different from imatinib?
Both drugs inhibit BCR-ABL, but nilotinib is a second-generation inhibitor designed for stronger BCR-ABL binding. It can be useful in some imatinib-resistant or intolerant cases, but it has important QT and vascular safety concerns.
Can nilotinib therapy ever be stopped?
Some carefully selected adult patients with chronic phase Ph+ CML who have taken nilotinib for at least 3 years and achieved sustained deep molecular response may be considered for treatment discontinuation under strict BCR-ABL monitoring. It should never be stopped casually without specialist supervision.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics
Katzung Basic & Clinical Pharmacology
